Durable overall survival benefit in patients >= 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: Updated results from the valor trial Meeting Abstract
| Authors: | Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E. J.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Cortes, J. E.; Roboz, G. J.; Craig, A. R.; Ward, R.; Smith, J.; Kantarjian, H. M.; Stuart, R. K. |
| Abstract Title: | Durable overall survival benefit in patients >= 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: Updated results from the valor trial |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446802161 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.903.903 |
| Notes: | Meeting Abstract: 903 -- Source: Wos |
